

The Department of Vermont Health Access Medical Policy

Subject: Home Uterine Activity Monitor
Last Review: January 3, 2017
Revision 4: December 10, 2015
Revision 3: August 20, 2014
Revision 2: October 10, 2012
Revision 1: April 12, 2011
Original Effective: 2004

***Please note: Most current content changes will be highlighted in yellow.**

Description of Service or Procedure

According to the Food and Drug Administration:

The home uterine activity monitor (HUAM) is an electronic system for at-home antepartum measurement of uterine contractions, data transmission by telephone to a clinical setting, and for data receive/display of the uterine contraction data at the clinic. The HUAM system comprises a tocotransducer, an at-home recorder, a modem, and a data receive/process/display computer/monitor.

The HUAM is a prescription-use only system that is indicated for use, in conjunction with standard high risk care, for the daily at-home measurement of uterine activity in pregnancies ≥ 24 weeks' gestation for women with a history of previous preterm birth. Uterine activity is displayed at a remote location to aid in the early detection of pre-term labor. (p. 2)

Disclaimer

Coverage is limited to that outlined in Medicaid Rule that pertains to the member's aid category. Prior Authorization (PA) is only valid if the member is eligible for the applicable item or service on the date of service.

Medicaid Rule

[7102.2](#) Prior Authorization Determination

[7103](#) Medical Necessity

Medicaid Rules can be found at <http://humanservices.vermont.gov/on-line-rules>



Coverage Position

Home Uterine Activity Monitoring may be covered for beneficiaries:

- When the Home Uterine Activity Monitor is prescribed by a licensed medical provider, enrolled in the Vermont Medicaid program, operating within their scope of practice in accordance with the Vermont State Practice Act, who is knowledgeable in the use of Home Uterine Activity Monitor and who provides medical care to the beneficiary. **AND**
- When the clinical criteria below are met.

Coverage Criteria

Home Uterine Activity Monitoring may be covered for members who:

- Are at least 24 and up to 36 weeks' gestation; **AND**
- Have a history of preterm birth and/or have preterm labor who are currently being followed by a physician who is knowledgeable in the management of patients with a history of preterm birth. **OR** Has documented risk factors that increase the risk of preterm birth including but not limited to: Placenta Previa, uterine anomalies, incompetent cervix, multiple gestation, complicated twin, or high-order multifetal pregnancy; **AND**
- Maintains daily contact with a nurse in the prescribing physician's office and have continued education on the signs and symptoms of preterm labor; **AND**
- Completes one or two one hour monitoring sessions per day, with data transmission to the medical provider immediately following each session; **AND**
- Tocolytic agents and other conventional methods to arrest progression of preterm labor have failed.

Clinical guidelines for repeat service or procedure

Clinical criteria must be met for medical necessity.

Type of service or procedure covered

Home Uterine Activity Monitors (HUAM) for members meeting the above clinical criteria.

Type of service or procedure not covered (this list may not be all inclusive)

- Non-FDA approved devices
- Home uterine activity monitors without associated nursing services.
- Prophylactic use of a HUAM has not been studied in high-order multiple gestations.
- HUAM as a screening tool for Pre-Term Labor (PTL)
- Prevention of PTL

References

American College of Obstetricians and Gynecologists. (2014). Multifetal gestations: twin, triplet, and higher-order multifetal pregnancies. National Guideline Clearinghouse Guideline Summary. Retrieved October 22, 2015, from: <http://www.guideline.gov/content.aspx?id=48025>

Dyson, D. C., Danbe, K. H., Bamber, J. A., Crites, Y. M., Field, D. R., Maier, J. A., et al. (1998). Monitoring women at risk for preterm labor. *The New England Journal of Medicine*, 338(1). Retrieved March 10, 2014, from: <http://www.nejm.org/doi/pdf/10.1056/NEJM199801013380103>

Food and Drug Administration. (2001). *Final guidance for industry and FDA reviewers: Class II Special Controls Guidance for Home Uterine Activity Monitors*. Retrieved March 10, 2014, from: <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM073596.pdf>

Health Net. (2015). Home uterine activity monitoring (HUAM). Notional Medical Policy NMP268. Retrieved October 22, 2015, from: <https://www.healthnet.com/static/general/unprotected/pdfs/national/policies/HomeUterineActivityMonitoring.pdf>

Innovative practice: ethical guidelines. ACOG Committee on Ethics. 2006, Reaffirmed 2012). *ACOG Committee Opinion No. 352*, 108(6). Retrieved March 10, 2014, from: <https://www.acog.org/~media/Committee%20Opinions/Committee%20on%20Ethics/co352.pdf?dmc=1&ts=20140310T1220280943>

Kalchbrenner, M. A. (2001). Clinical Review of home uterine activity monitoring (HUAM). *Journal of the American Osteopathic Association*, 101(2). Retrieved March 10, 2014, from: <http://jaoa.org/article.aspx?articleid=2092399&resultClick=1>

Urquhart, C., Currell, R., Harlow, F. & Callow, L. Home Uterine Monitoring for Detecting Preterm Labour (review). In: The Cochrane Library, Issue 5, 2012. Chichester: Wiley. Updated Quarterly.

This document has been classified as public information.